Lindsay Fischer

Heather Santone breaks down some of the barriers that geriatric patients with cancer face—and how nurse navigators can help them overcome these obstacles.

Lorazepam was associated with worse survival outcomes for patients with pancreatic cancer, while alprazolam was associated with improved outcomes.

The FDA has approved motixafortide in combination with filgrastim to mobilize hematopoietic stem cells in multiple myeloma transplantation, based on findings from the phase 3 GENESIS trial.

Elizabeth Aronson, MSN, FNP-BCN, OCN, discusses how the recent approvals of elranatamab and talquetamab are changing the treatment landscape for patients with multiple myeloma.

Stronger interventions are needed to improve adjuvant treatment rates among breast cancer survivors.

Younger populations and African American patients are most impacted.

White patients have the oldest average at diagnosis at 64.5 years, whereas Hispanic or Latino patients have the youngest average age at 57.2 years.

In 2021, immune checkpoint inhibitors were used by 12.1% of patients with cancer—however, these agents represent 36.2% of all oncology medication costs.

Shawna Douglas, BSN, RN, discusses the role that nurse navigators play in caring for patients with head and neck cancer.

Linda Bloom, MPA, RN, OCN, explains how amplifiers and audio interpreter tablets can be vital resources during cancer care.

Effective interventions exist for cancer-related sexual dysfunction, but higher-quality research is still needed to optimize management.

Black patients with multiple myeloma may be at a higher-risk for bortezomib-induced peripheral neuropathy compared with non-Black patients.

The FDA has approved luspatercept to treat anemia in patients with lower-risk myelodysplastic syndromes.

A retrospective study highlights the need to examine sustainable reimbursement structures for telehealth services.

Experts with the Society for Integrative Oncology and the American Society of Clinical Oncology recommend mindfulness-based interventions to help patients with cancer manage anxiety and depression symptoms.

Jennifer Cargile, MEd, CCC-SLP, shares some signs and symptoms of cancer-related cognitive impairment that the oncology nurse should be looking out for.

ASCO has updated its recommendations for systemic therapies in melanoma.

Circulating tumor DNA analysis is playing an increasingly important role in colorectal cancer treatment decision-making.

Leana Cabrera Chien, MSN, RN, GCNS-BC, GNP-BC; and William Dale, MD, PD, discuss the new ASCO geriatric assessment guidelines and what they mean for nurses.

The FDA has approved a liver-directed therapy to treat metastatic uveal melanoma with hepatic metastases.

The FDA has granted accelerated approval to elranatamab-bcmm to treat adults with relapsed or refractory multiple myeloma who have already undergone 4 prior lines of treatment.

The FDA has issued a complete response letter to the new drug application for avasopasem manganese to manage oral mucositis in patients with locally advanced head and neck cancer undergoing radiation.

Linda Bloom, MPA, RN, OCN, highlights how tools such as audio interpretation technology and clear masks can help nurses and patients overcome communication barriers in oncology.

The FDA has approved niraparib and abiraterone acetate to treat patients with deleterious or suspected deleterious BRCA-positive mCRPC, as detected by an FDA-approved test.

The FDA has approved the therascreen PDGFRA kit to identify patients with gastrointestinal stromal tumors who may benefit from treatment with avapritinib.

Oncology nurses make the case for nurse intervention with direct-to-consumer genomic testing.

Talquetamab has received accelerated approval for patients with relapsed or refractory multiple myeloma.

The FDA has granted regular approval to pralsetinib as a treatment for adults with metastatic RET fusion-positive non-small cell lung cancer.

A brain tumor diagnosis can be daunting. Nurses are on the front lines connecting patients to available resources and walking them through the best treatment options.

A single-arm study pilot study showed that patients' well-being scores significantly improved with the introduction of aromatherapy.